



## Humoral and Cellular Response after Vaccination

Guest Editors:

**Dr. Adrian Onu**

1. "Cantacuzino" Institute, 050096  
Bucharest, Romania  
2. Faculty of Pharmacy, Titu  
Maiorescu University, 040317  
Bucharest, Romania

**Dr. Iuliana Caras**

Cantacuzino, National Medical-  
Military Institute for Research and  
Development, 050096 Bucharest,  
Romania

Deadline for manuscript  
submissions:

**30 November 2024**

### Message from the Guest Editors

Dear Colleagues,

Efficient vaccination relies on inducing a robust adaptive immune response, both cellular and humoral, each playing a specific role in preventing or controlling infection. The challenge in developing an effective vaccine lies in finding the right balance between the different types of immune response required. To evaluate a vaccine, a range of methods have been developed. Immunization markers are constantly evolving, and sometimes newer markers from large data sets, identified through principal component analysis, replace traditional ones. In addition to the polarization of the immune response, the impact of immunization on innate immunity (trained immunity) calls for the use of additional instruments and concepts to assess vaccine effectiveness.

This special issue seeks to provide an overview of the current methodology for evaluating vaccines, from the design phase to clinical trials. The proposed articles aim to offer relevant insights into these concepts in the field of modern vaccination.

Dr. Adrian Onu  
Dr. Iuliana Caras  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)